+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
543499 ACHYUT

Achyut Healthcare Share Price

 

 

Achyut Healthcare live price: ₹8.37. It opened at ₹9 vs previous close ₹9; intraday high/low: ₹10/₹8. The 50 & 200 DMA stand at ₹6.33/₹5.48.

Achyut Healthcare Performance

  • Today's Low
  • ₹8
  • Today's High
  • ₹10
  • 52 Week Low
  • ₹3
  • 52 Week High
  • ₹10
  • Open Price₹9
  • Previous Close₹9
  • Volume1,094,214
  • 50 DMA₹6.33
  • 100 DMA₹5.91
  • 200 DMA₹5.48

Achyut Healthcare Chart

Investment Returns

  • Over 1 Month + 47.36%
  • Over 3 Month + 52.18%
  • Over 6 Month + 48.93%
  • Over 1 Year + 146.18%

Smart Investing Starts Here Start SIP with Achyut Healthcare for Steady Growth!

Invest Now

Achyut Healthcare Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 687.2
  • PEG Ratio
  • -
  • Market Cap Cr
  • 202
  • P/B Ratio
  • 5.8
  • Average True Range
  • 0.65
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • 0.56
  • RSI
  • 72.22
  • MFI
  • 68.04

Achyut Healthcare Financials

Achyut Healthcare Technicals

EMA & SMA

Current Price
₹8.37
-0.76 (-8.32%)
pointer
  • Bearish Moving Average 2
  • Bullish Moving Average 14
  • 20 Day
  • ₹7.20
  • 50 Day
  • ₹6.30
  • 100 Day
  • ₹5.90
  • 200 Day
  • ₹5.50

Resistance and Support

8.88 Pivot Speed
  • R3 11.35
  • R2 10.70
  • R1 9.53
  • S1 7.71
  • S2 7.06
  • S3 5.89

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Achyut Healthcare has an operating revenue of Rs. 11.59 Cr. on a trailing 12-month basis. An annual revenue growth of 202% is outstanding, Pre-tax margin of 3% needs improvement, ROE of 0% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 54% and 64% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 23% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 47 which is a POOR score indicating inconsistency in earnings, a RS Rating of 94 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 60 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Achyut Healthcare Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-27 Audited Results
2026-01-21 Quarterly Results & Preferential issue (Revised) issue in the ratio of 1:2 of Rs. 10/-.
2025-10-16 Half Yearly Results
2025-09-02 A.G.M.
2025-05-29 Audited Results
Date Purpose Remarks
2024-12-10 Split Rs.0.00 split from Rs. 10/- to Re. 1/-.
Date Purpose Remarks
2024-12-10 Bonus Re.0.00 issue in the ratio of 4:10 of Re. 1/-.
2023-04-25 Bonus Rs.0.00 issue in the ratio of 1:2 of Rs. 10/-.

Achyut Healthcare Shareholding Pattern

47.4%
5.13%
42.83%
4.64%

Achyut Healthcare FAQs

Achyut Healthcare share price is ₹8 As on 25 June, 2026 | 08:10

The Market Cap of Achyut Healthcare is ₹202 Cr As on 25 June, 2026 | 08:10

The P/E ratio of Achyut Healthcare is 687.2 As on 25 June, 2026 | 08:10

The PB ratio of Achyut Healthcare is 5.8 As on 25 June, 2026 | 08:10

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23